miRagen Therapeutics to Present at Biotech Showcase 2012

BOULDER, Colo.--(BUSINESS WIRE)-- MiRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, will present at the Biotech Showcase 2012 in San Francisco. Dr. Marshall’s presentation will take place on Monday, January 9, 2012, at 10:45 a.m. PST at the Parc 55 Wyndham hotel and will provide an overview of the company, including key events, accomplishments and its focus in 2012.

About microRNAs: MicroRNAs have emerged as an important class of small RNAs encoded in the genome. They act to control the expression of sets of genes and entire pathways and are thus thought of as master regulators of gene expression. Recent studies have demonstrated that microRNAs are associated with many disease processes. Because they are single molecular entities that dictate the expression of fundamental regulatory pathways, microRNAs represent potential drug targets for controlling many biologic and disease processes.

About miRagen Therapeutics: MiRagen Therapeutics, Inc., a pre-clinical stage biopharmaceutical company, was founded in 2007 to develop innovative microRNA-based therapeutics for cardiovascular and muscle disease. MicroRNAs are short, single-stranded RNA molecules encoded in the genome that regulate gene expression and play a vital role in influencing cardiovascular and muscle disease. Cardiovascular disease is the leading cause of death globally and represents an enormous burden on global healthcare systems. MiRagen combines world recognized leadership in cardiovascular medicine with unprecedented in-house expertise in microRNA biology and chemistry. In October 2011, miRagen and Les Laboratoires Servier, a leading European pharmaceutical company, entered into a strategic alliance for the research and development of microRNA-based therapeutics in cardiovascular disease. For more information, please visit www.miragentherapeutics.com.



CONTACT:

miRagen Therapeutics, Inc.
Tammy Egan, 720-407-4588
Executive Administrator
[email protected]

KEYWORDS:   United States  North America  California  Colorado

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology

MEDIA:

Logo
 Logo

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.